Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer

Zura Bio (NASDAQ:ZURA) had its price target reduced by analysts at Oppenheimer from $16.00 to $15.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 157.16% from the stock’s current price.

Other analysts have also issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zura Bio in a report on Friday, January 9th. Leerink Partners raised shares of Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Finally, Wedbush started coverage on shares of Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Zura Bio currently has an average rating of “Moderate Buy” and an average price target of $11.40.

Zura Bio Stock Down 4.7%

ZURA stock traded down $0.29 during mid-day trading on Friday, reaching $5.83. 238,620 shares of the company traded hands, compared to its average volume of 660,570. The stock has a market cap of $379.26 million, a price-to-earnings ratio of -9.02 and a beta of 0.18. The firm’s 50 day moving average price is $6.16 and its 200 day moving average price is $4.51. Zura Bio has a fifty-two week low of $0.97 and a fifty-two week high of $7.44.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Insider Activity at Zura Bio

In related news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of Zura Bio stock in a transaction dated Thursday, February 26th. The stock was bought at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the transaction, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 14.23% of the stock is owned by insiders.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently modified their holdings of ZURA. Seven Fleet Capital Management LP bought a new stake in Zura Bio during the 4th quarter worth approximately $872,000. XTX Topco Ltd purchased a new position in Zura Bio during the fourth quarter worth about $348,000. Suvretta Capital Management LLC boosted its position in shares of Zura Bio by 1.7% during the 4th quarter. Suvretta Capital Management LLC now owns 5,567,001 shares of the company’s stock valued at $29,171,000 after acquiring an additional 94,110 shares during the last quarter. Quadrature Capital Ltd purchased a new position in shares of Zura Bio during the fourth quarter worth about $192,000. Finally, Millennium Management LLC increased its holdings in shares of Zura Bio by 75.1% in the 4th quarter. Millennium Management LLC now owns 1,032,680 shares of the company’s stock worth $5,411,000 after buying an additional 442,980 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.